Cargando…

COVID-19 after rituximab therapy in cSLE patients

Childhood-onset systemic lupus erythematosus (cSLE) is an autoimmune disease associated with significant morbidity and mortality. Rituximab is a B-cell depleting therapy utilized in the treatment of SLE. In adults, rituximab has been associated with increased risk of adverse outcomes in patients who...

Descripción completa

Detalles Bibliográficos
Autores principales: Nelson, Meghan Corrigan, Manos, Cynthia K., Flanagan, Elaine, Prahalad, Sampath
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10285438/
https://www.ncbi.nlm.nih.gov/pubmed/37362155
http://dx.doi.org/10.1177/25151355231181242
_version_ 1785061608220786688
author Nelson, Meghan Corrigan
Manos, Cynthia K.
Flanagan, Elaine
Prahalad, Sampath
author_facet Nelson, Meghan Corrigan
Manos, Cynthia K.
Flanagan, Elaine
Prahalad, Sampath
author_sort Nelson, Meghan Corrigan
collection PubMed
description Childhood-onset systemic lupus erythematosus (cSLE) is an autoimmune disease associated with significant morbidity and mortality. Rituximab is a B-cell depleting therapy utilized in the treatment of SLE. In adults, rituximab has been associated with increased risk of adverse outcomes in patients who develop coronavirus disease 2019 (COVID-19). We aimed to assess the impact of prior rituximab treatment on clinical outcomes from Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection in children with SLE. To describe the impact of rituximab on outcomes from SARS-CoV-2 infection, we conducted a retrospective study of pediatric SLE patients in our center diagnosed with COVID-19 who had previously received rituximab between February 2019 and October 2022. Patients’ clinical characteristics, disease activity, and outcomes were assessed. Of the eight subjects assessed, five required hospitalizations for COVID-19, four required ICU admission, and two were seen in the emergency department for their symptoms. One patient ultimately expired from her illness. The median time between rituximab administration and COVID-19 diagnosis was 3 months. We assessed the clinical outcomes, including the need of ICU admission and fatal outcome, of COVID-19 in our cSLE patient population after rituximab administration. Approximately 60% of our patients required hospitalization for their illness, and seven out of eight patients required healthcare utilization to include hospitalization and/or emergency department visits.
format Online
Article
Text
id pubmed-10285438
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-102854382023-06-22 COVID-19 after rituximab therapy in cSLE patients Nelson, Meghan Corrigan Manos, Cynthia K. Flanagan, Elaine Prahalad, Sampath Ther Adv Vaccines Immunother Case Series Childhood-onset systemic lupus erythematosus (cSLE) is an autoimmune disease associated with significant morbidity and mortality. Rituximab is a B-cell depleting therapy utilized in the treatment of SLE. In adults, rituximab has been associated with increased risk of adverse outcomes in patients who develop coronavirus disease 2019 (COVID-19). We aimed to assess the impact of prior rituximab treatment on clinical outcomes from Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection in children with SLE. To describe the impact of rituximab on outcomes from SARS-CoV-2 infection, we conducted a retrospective study of pediatric SLE patients in our center diagnosed with COVID-19 who had previously received rituximab between February 2019 and October 2022. Patients’ clinical characteristics, disease activity, and outcomes were assessed. Of the eight subjects assessed, five required hospitalizations for COVID-19, four required ICU admission, and two were seen in the emergency department for their symptoms. One patient ultimately expired from her illness. The median time between rituximab administration and COVID-19 diagnosis was 3 months. We assessed the clinical outcomes, including the need of ICU admission and fatal outcome, of COVID-19 in our cSLE patient population after rituximab administration. Approximately 60% of our patients required hospitalization for their illness, and seven out of eight patients required healthcare utilization to include hospitalization and/or emergency department visits. SAGE Publications 2023-06-21 /pmc/articles/PMC10285438/ /pubmed/37362155 http://dx.doi.org/10.1177/25151355231181242 Text en © The Author(s), 2023 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Case Series
Nelson, Meghan Corrigan
Manos, Cynthia K.
Flanagan, Elaine
Prahalad, Sampath
COVID-19 after rituximab therapy in cSLE patients
title COVID-19 after rituximab therapy in cSLE patients
title_full COVID-19 after rituximab therapy in cSLE patients
title_fullStr COVID-19 after rituximab therapy in cSLE patients
title_full_unstemmed COVID-19 after rituximab therapy in cSLE patients
title_short COVID-19 after rituximab therapy in cSLE patients
title_sort covid-19 after rituximab therapy in csle patients
topic Case Series
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10285438/
https://www.ncbi.nlm.nih.gov/pubmed/37362155
http://dx.doi.org/10.1177/25151355231181242
work_keys_str_mv AT nelsonmeghancorrigan covid19afterrituximabtherapyincslepatients
AT manoscynthiak covid19afterrituximabtherapyincslepatients
AT flanaganelaine covid19afterrituximabtherapyincslepatients
AT prahaladsampath covid19afterrituximabtherapyincslepatients